Survivin – biology and potential as a therapeutic target in oncology

Abstract

Chun Hei Antonio Cheung,1,2 Chien-Chang Huang,3 Fang-Ying Tsai,4 Jane Ying-Chieh Lee,1 Siao Muk Cheng,2 Yung-Chieh Chang,1 Yi-Chun Huang,1 Shang-Hung Chen,5 Jang-Yang Chang3,6 1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 3National Institute of Cancer Research, National Health Research Institutes, Tainan, 4South East Asian Health Education Center in Taiwan (SEAHECT), College of Medicine, National Cheng Kung University, Tainan, 5Division of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, 6Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China Abstract: Survivin is a member of the inhibitor-of-apoptosis proteins (IAPs) family; its overexpression has been widely demonstrated to occur in various types of cancer. Overexpression of survivin also correlates with tumor progression and induces anticancer drug resistance. Interestingly, recent studies reveal that survivin exhibits multiple pro-mitotic and anti-apoptotic functions; the differential functions of survivin seem to be caused by differential subcellular localization, phosphorylation, and acetylation of this molecule. In this review, the complex expression regulations and post-translational modifications of survivin are discussed. This review also discusses how recent discoveries improve our understanding of survivin biology and also create opportunities for developing differential-functioned survivin-targeted therapy. Databases such as PubMed, Scopus® (Elsevier, New York, NY, USA), and SciFinder® (CAS, Columbus, OH, USA) were used to search for literature in the preparation of this review. Keywords: survivin, BIRC5, IAP, XIAP, caspase-9, Samc, DIABLO